

# Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors

Yang Gao, Tinghu Zhang, Hideki Terai, Scott B. Ficarro, Nicholas Kwiatkowski, Ming-Feng Hao, Bandana Sharma, Camilla L. Christensen, Edmond Chipumuro, Kwok-kin Wong, Jarrod A. Marto, Peter S. Hammerman, Nathanael S. Gray, Rani E. George

*Repligen Corp. now owns the life sciences PAT product portfolio of 908 Devices Inc. Please contact Repligen for further inquiries.*

*Cell Chemical Biology, Just Accepted Manuscript*

DOI: [doi.org/10.1016/j.chembiol.2017.11.007](https://doi.org/10.1016/j.chembiol.2017.11.007)

Publication Date (Web): December 21, 2017

Copyright © 2017 Elsevier Ltd.

## Contact

Repligen Corporation  
685 Route 202/206  
Bridgewater, NJ, USA 08807  
[analytics-support@repligen.com](mailto:analytics-support@repligen.com)  
(908) 707-1009

## Abstract

Irreversible inhibition of transcriptional cyclin-dependent kinases (CDKs) provides a therapeutic strategy for cancers that rely on aberrant transcription; however, lack of understanding of resistance mechanisms to these agents will likely impede their clinical evolution. Here, we demonstrate upregulation of multidrug transporters ABCB1 and ABCG2 as a major mode of resistance to THZ1, a covalent inhibitor of CDKs 7, 12, and 13 in neuroblastoma and lung cancer. To counter this obstacle, we developed a CDK inhibitor, E9, that is not a substrate for ABC transporters, and by selecting for resistance, determined that it exerts its cytotoxic effects through covalent modification of cysteine 1039 of CDK12. These results highlight the importance of considering this common mode of resistance in the development of clinical analogs of THZ1, identify a covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux, and demonstrate that target deconvolution can be accomplished through selection for resistance.

[Click here](#) to view the entire article.

